Taylor & Francis Inc Sivumäärä: 172 sivua Asu: Kovakantinen kirja Painos: 1 Julkaisuvuosi: 2006, 13.12.2006 (lisätietoa) Kieli: Englanti
Chronic Myeloid Leukemia (CML) remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level and has been used by researchers to develop a variety of therapies and therapeutic assessment methods. This concise, readable guide assembles and synthesizes the latest developments and trends in the treatment of CML and provides an authoritative and convenient summary of the latest progress in imatinib trials, the molecular monitoring of CML responses, and the engineering of new therapies to overcome resistance and improve patient care.
Providing critical insight and exploration of models that will enhance the cancer community at large, this source:
stands as the only source to focus on post-Gleevec developments in CML therapeutics
collects information from the forefront of the field—helping busy clinicians make informed management decisions
supplies critical research from recognized opinion leaders on the topic
provides an overview of the current status of new transplant modalities
